Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3913]

Acalabrutinib monotherapy shows significant benefit in relapsed or refractory...

Dr Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

$Acalabrutinib monotherapy shows significant benefit in relapsed or refractory chronic lymphocytic leukaemia ( Dr Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )$

Imetelstat provides durable transfusion independence in heavily transfused non...

Dr Pierre Fenaux - Hôpital St Louis and Paris University, Paris, France

Imetelstat provides durable transfusion independence in heavily transfused non-del(5q) LR-MDS R/R to ESAS ( Dr Pierre Fenaux - Hôpital St Louis and Paris University, Paris, France )

D-VTd in induction prior to and consolidation after ASCT improves PFS and depth...

Prof Philippe Moreau - Chu Nantes, Nantes, France

D-VTd in induction prior to and consolidation after ASCT improves PFS and depth of response with acceptable safety ( Prof Philippe Moreau - Chu Nantes, Nantes, France )

Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with...

Dr Kirsten Fischer - Uniklinik Köln, Cologne, Germany

Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreated CLL and comorbidities ( Dr Kirsten Fischer - Uniklinik Köln, Cologne, Germany )

Most pregnancies in CML patients resulted in normal childbirth: Analysis of 305...

Dr Ekaterina Chelysheva - National Research Center for Hematology, Moscow...

Most pregnancies in CML patients resulted in normal childbirth: Analysis of 305 cases of the European Leukemia Net registry ( Dr Ekaterina Chelysheva - National Research Center for Hematology, Moscow, Russian Federation )

Intervention for AML patients with MRD can result in improved survival

Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart...

Intervention for AML patients with MRD can result in improved survival ( Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, USA )

BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA...

Prof Hope Rugo - University of California, San Francisco, USA

BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR /HER2- advanced breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )

Advances in PARP inhibitor use for metastatic breast cancer

Prof Hope Rugo - University of California, San Francisco, USA

Advances in PARP inhibitor use for metastatic breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )

Margetuximab for the treatment of HER2-positive breast cancer

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...

Margetuximab for the treatment of HER2-positive breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )

The future of PARP inhibitors in metastatic breast cancer

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...

The future of PARP inhibitors in metastatic breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )

DORA: Using olaparib alone or with durvalumab in platinum responsive advanced...

Dr Tira Tan - National Cancer Centre, Singapore

DORA: Using olaparib alone or with durvalumab in platinum responsive advanced triple-negative breast cancer ( Dr Tira Tan - National Cancer Centre, Singapore )

EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in...

Dr Johannes Ettl - Technical University, Munich, Germany

EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in patients with advanced breast cancer ( Dr Johannes Ettl - Technical University, Munich, Germany )

More from ecancer